This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. The ‘Sectoral Systems of Innovation and the UK’s Competitiveness’ reports assess the value-added per capita of each sector and how they compare internationally.
The competition saw 23 healthcare startups across biopharma, medical devices, and health tech geared for consumers/employers as well as payers/providers pitch their business plans to teams of investor judges.
As professionals with more than a half-century between us working in biopharma and diagnostics marketing and communications from the corporate (Ayaz Malik) and agency (Sandra Stahl) sides, we believe nurturing multigenerational teams is an especially powerful yet underutilized strategy for our industry. To be sure, steps have been taken.
Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis.
Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. Innovation Is Expanding, But Healthcare Systems Are Slow to Adapt. Driving scale in a slow-moving healthcare ecosystem is not just a challenge for cell and gene therapies.
Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. Historically, competitive and market analysis data has been stored in spreadsheets. Truly understanding the competitive landscape and market environment.
These data are astonishing, given the perception that Big Pharma is the main driver of biopharma innovation. Meanwhile, the number of companies launching their first drug during the decade preceding 2018 more than tripled. Not anymore. Despite this, most of the trade chatter around launch excellence assumes the launcher is big.
The company intends to invest approximately $90 million at its site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026. They drive competition and cost savings, helping to address the rising financial pressures faced by global healthcare systems.
healthcare payers and providers are consolidating at a dizzying clip as they seek to gain market share, increase access to care and secure clinical control to improve health outcomes. CVS’ bid for Oak Street is in keeping with nearly two decades of evolution toward becoming an integrated payer and provider.
sarah.caldwell@veeva.com SARAH CALDWELL General Manager Veeva Crossix Analytic Consumers’ TV viewing habits are changing, and streaming video continues to catapult in popularity, unearthing new opportunities for biopharma advertisers to reach patients in more targeted ways. According to Nielsen, streaming accounts for 38% of viewership hours.
Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.
Either way, competition over employed providers among Medicare Advantage plans has only begun to heat up and UnitedHealth remains the plan to beat. Clarivate Associate Healthcare Research & Data Analysts Anubhav Sharma and Prashanth Jain contributed to this report. Medicare provider competition appeared first on Clarivate.
Now, as the President of Accord BioPharma , the U.S. PM360: From your time at Roche when you were dealing with biosimilars as potential competition to now leading the launch of biosimilars at Accord and Intas, how have you seen the marketplace for biosimilars evolve over that time? Look, competition is healthy.
OFF-X is already integrated with several Cortellis products, including Cortellis Drug Discovery Intelligence and Cortellis Competitive Intelligence. As a next step in this journey, Bioinfogate will be fully integrated into the Clarivate product portfolio and renamed.
billion by 2032, according to Towards Healthcare. On the other hand, the author explained that these challenges are anticipated to be addressed through advances in technology, industry effort on implementation of standardisation and increased competition in the market. Could centrifugal bioreactor accelerate cell-therapy manufacturing?
Following the acquisition of Dialog Solutions as part of the ProQuest M&A in December 2021, Dialog Solutions products and services will be folded into the Clarivate portfolio of offerings for Life Sciences & Healthcare. To learn more about the Dialog platform, visit: here.
Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). However, with rapid growth comes growing pains.
May 9, 2024 /PRNewswire/ — VUE Health, a Boston-based healthcare advertising agency, has hired Zara Baker as Chief Digital Innovation Officer. Before that, she was the head of omnichannel strategy at Ionis Pharma and held senior digital roles at various healthcare and biopharma companies. SOURCE VUE Health
I recently sat down with Erica Taylor, PhD, Vice President and Chief Marketing Officer at Genentech, to talk about the future of biopharma marketing and creating more meaningful content. Pooja Ojala: How do you approach marketing to adapt to today’s healthcare landscape?
Regardless of the reasons, investors, pharma, and research organizations are recognizing that advanced digital health tools will be a significant competitive advantage and generate meaningful return on investment (ROI) in an industry that is becoming more personalized and specialized.
Embracing a mindset shift to pave the way for effective engagement models In an incredibly competitive market, field teams now must work harder than ever to stand out. Every interaction field teams have with healthcare professionals needs to add value and provide customers with the right material to inform key decisions.
The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. By end of year, as many as ten adalimumab biosimilars could be on the U.S. from 91% in 2023 to 36% by 2031.
Companies need to carefully assess the value of the assets being acquired or licensed, considering factors such as the stage of development, market potential, the competitive landscape and intellectual property protection.
In a fiercely competitive U.S. healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. Christopher Silva, Senior Healthcare Research Analyst.
In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience.
While the global biopharma industry retains its huge dependence on the U.S. This should, at least in theory, make them an appealing target for biopharma companies looking to expand beyond the hugely competitive markets of the U.S., market, emerging markets present great opportunities for biotech and pharmaceutical companies.
According to figures from the Healthcare Research & Data Analytics team at Clarivate, the top three best-selling products for Pfizer, AbbVie, Merck/MSD and Bristol Myers Squibb contributed more than half their revenue in 2022, ranging from 53.3% of AbbVie’s $51.8 billion in revenue to a whopping 67.2% for Bristol Myers Squibb’s $44.7
The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The lengthy validation of defossilised organic chemicals and plastics for the healthcare sector will take several years. The path to real zero.
Doubling down on strategic therapeutic areas Pharma once again finds itself having to narrow its sights on partnerships that deliver the next blockbuster and enable differentiation from the competition—all while navigating increasing regulatory scrutiny and shifting patient and payer expectations.
She has experience on issues arising during the lifecycle of medicinal products, including optimisation of IP regulatory rights, advertising, product liability, competition and market access issues. Chris was named a ‘Rising Star’ in the 2022 Legal 500 Rankings for Life Sciences and Healthcare. References/Endnotes. Lausuntopalvelu.fi.
1 As revolutionary upstream and downstream technologies become a reality, biopharma companies will need to determine how best to integrate them into their current systems. 2 Capabilities in suspension cell lines and proprietary cell lines are becoming increasingly important to competitiveness within the gene therapy industry.
In the pharmaceutical sector, this evolved further with privacycompliant data enrichment, enabling hyper-personalized messaging for healthcare providers (HCPs). By tracking preferences and behaviors, companies tailored interactions to make them more meaningful and effective.
In recent years, FDA has increasingly shown an openness to surrogate endpoints as the basis for approval of a therapy,” said Bethany Kiernan, Director of Healthcare Research Analytics for Infectious, Niche and Rare Diseases at Clarivate.
exclusions exist for orphan drug designation and biosimilar competition ). However, the ultimate impact of this program should have far-reaching effects for pharmaceutical companies and the broader healthcare system that bear monitoring as the IRA’s multi-year implementation schedule unfolds.
September 8, 2021 Over the years, the healthcare industry has progressively grown more and more complex, from the increasing influence of managed care companies to intensifying governmental regulations to new data sources. In parallel with this growing industry-wide complexity has been the call to further simplify sales compensation plans.
For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.
As the pharmaceutical landscape grows more dynamic and competitive, life sciences companies are increasingly expected to develop more innovative brand launches, whilst juggling more complexity in marketing and interactions with healthcare professionals (HCPs).
You are going to see a dramatic change in leadership’s urgency to leverage AI This new creative AI era will fuel massive advances in personalized customer service, drive new business models, improve real-time modeling ( Southwest Airlines ) and pave the way for breakthroughs in healthcare and biopharma from Google ‘s DeepMind.
In therapeutic areas where there is competition for trial participants (e.g. If trial sponsors can access this data in a trusted and layered way, RWD will save dollars and lives, a win-win for all stakeholders in the healthcare ecosystem. oncology), trial productivity is essential.
The event is a key platform for global supply chain connections, offering unmatched opportunities to form partnerships, secure contracts, and stay competitive. However, the venture capital branches of leading pharmaceutical firms are proving to be innovation engines, vital in fostering advances and addressing key healthcare issues.
CVS Caremark manages pharmacy benefits for Molina Healthcare, Centene and Aetna, which hold a Medicaid contract in states that are transitioning to a single PBM. If more states move to a single PBM model, there could be rising competition to win a state contract that guarantees significant membership for a long period of time.
As part of our Drugs to Watch series, which reviews therapies expected to have significant impact on healthcare markets, Clarivate oncology experts sifted through the more than 2,800 abstracts that were accepted for presentation at the ESMO 2021 Virtual Conference and selected their top picks.
Learn about how AI is helping companies right now, what to know about its benefits and challenges, and what’s needed to implement AI in biopharma research. AI and its healthcare applications will continue to evolve, but you can already realize many potential benefits. How is AI used in the pharmaceutical industry?
This article outlines how developers can utilize sustainability initiatives to boost revenue, reduce costs, and advance innovation, ensuring a strategic, long-term, and more sustainable position in today’s competitive landscape.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content